BRD4 and cancer: Despite showing lower potency than previouslyreported JQ1-based degrader MZ1, the RNF4-based PROTAC 19 (Table 2, entry 19)could degrade BRD4 in a time and dose-responsive manner in 231MFPbreast cancer cells.80